Cargando…

Targeted Approaches Applied to Uncommon Diseases: A Case of Salivary Duct Carcinoma Metastatic to the Brain Treated with the Multikinase Inhibitor Neratinib

Salivary duct carcinoma is a rare malignancy associated with hormone receptor and human epidermal growth factor receptor 2 (HER2) overexpression. Local surgical control is the cornerstone of therapy, but a subset of patients develops metastatic disease portending a poor prognosis and limited managem...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sorenson, Karl R., Piovezani Ramos, Guilherme, Villasboas Bisneto, Jose Caetano, Price, Katharine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582428/ https://www.ncbi.nlm.nih.gov/pubmed/28878657 http://dx.doi.org/10.1159/000479499

Ejemplares similares

Metastatic Salivary Duct Carcinoma with ERBB2 Amplification and Sequential Response to Ado-Trastuzumab Emtansine and Neratinib: A Case Report
por: Asper, Nora, et al.
Publicado: (2023)

Neratinib for breast cancer
Publicado: (2019)

Transglutaminase-2 mediates acquisition of neratinib resistance in metastatic breast cancer
por: Shinde, Aparna, et al.
Publicado: (2022)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
por: Eli, Lisa D., et al.
Publicado: (2022)

Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma
por: Jeong, Il Seok Daniel, et al.
Publicado: (2020)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
por: Alkhezayem, Sara, et al.
Publicado: (2020)

Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2015)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

Neratinib protects pancreatic beta cells in diabetes
por: Ardestani, Amin, et al.
Publicado: (2019)

Successful Treatment with Nivolumab in a Patient with Metastatic Salivary Duct Carcinoma
por: Sato, Tsuyoshi, et al.
Publicado: (2021)

Systemic therapy for recurrent or metastatic salivary gland malignancies
por: Chintakuntlawar, Ashish V., et al.
Publicado: (2016)

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
por: Chow, L W-C, et al.
Publicado: (2013)

Multikinase Inhibitor Treatment in Thyroid Cancer
por: Ancker, Ole Vincent, et al.
Publicado: (2019)

Rare complications of multikinase inhibitor treatment
por: Pitoia, Fabián, et al.
Publicado: (2018)

Disease characterization in liquid biopsy from HER2-mutated, non-amplified metastatic breast cancer patients treated with neratinib
por: Shishido, Stephanie N., et al.
Publicado: (2022)

Profile of neratinib and its potential in the treatment of breast cancer
por: Feldinger, Katharina, et al.
Publicado: (2015)

Neratinib-Induced Duodenal Ulcer: A Case Report
por: Moftakhar, Bahar, et al.
Publicado: (2020)

Primary and Secondary/ Metastatic Salivary Duct Carcinoma Presenting within the Sinonasal Tract
por: Agaimy, Abbas, et al.
Publicado: (2021)

Acinic Cell Carcinoma of the Salivary Gland with Metastatic Spread to the Pancreas
por: Geiger, Jessica L., et al.
Publicado: (2014)

Affections of the salivary ducts in buffaloes
por: Misk, N.A., et al.
Publicado: (2014)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

An uncommon cause of common bile duct stenosis diagnosed and treated by cholangioscopy
por: Tanţău, Marcel, et al.
Publicado: (2018)

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
por: Kumar, R, et al.
Publicado: (2009)

Inositol polyphosphate multikinase signaling in the regulation of metabolism
por: Lee, Joo-Young, et al.
Publicado: (2012)

Multikinase inhibitors use in differentiated thyroid carcinoma
por: Jasim, Sina, et al.
Publicado: (2014)

Daily Management of Patients on Multikinase Inhibitors’ Treatment
por: Colombo, Carla, et al.
Publicado: (2022)

Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023)

Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
por: Oaknin, Ana, et al.
Publicado: (2020)

Salivary duct carcinoma of parotid gland
por: Kinnera, Vijay Sreedhar Babu, et al.
Publicado: (2009)

Salivary duct carcinoma of the parotid gland
por: Mlika, Mona, et al.
Publicado: (2012)

Salivary duct carcinoma of accessory parotid
por: Al-Hashim, Mohammed A., et al.
Publicado: (2017)

Case of Salivary Calculus in the Parotid Duct
por: Bell, Joseph
Publicado: (1875)

Salivary duct stenosis: diagnosis and treatment
por: Koch, M., et al.
Publicado: (2017)

Emerging role of multikinase inhibitors for refractory thyroid cancer
por: Perez, Cesar A, et al.
Publicado: (2012)

Exploring Selectivity of Multikinase Inhibitors across the Human Kinome
por: Miljković, Filip, et al.
Publicado: (2018)

Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib
por: Lin, Tong, et al.
Publicado: (2017)

Targeting RET-rearranged lung cancers with multikinase inhibitors
por: Sabari, Joshua K., et al.
Publicado: (2017)

Timing of multikinase inhibitor initiation in differentiated thyroid cancer
por: Brose, Marcia S, et al.
Publicado: (2017)

Gastrointestinal Tract Homeostasis: The Role of the Inositol Polyphosphate Multikinase
por: Saiardi, Adolfo
Publicado: (2022)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2q321j331iofgfu34puu31t6m5